Sema3a As a Novel Therapeutic Option for High Glucose-Suppressed Osteogenic Differentiation in Diabetic Osteopathy

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2019 Sep 5

PMID 31481931

Citations 6

Authors

Lixia Zhang

Lili Zheng

Chong Li

Zhifang Wang

Shan Li

Lijun Xu

Affiliations

Soon will be listed here.

Abstract

Diabetic osteopathy is a common comorbidity of diabetes mellitus, with skeletal fragility, osteoporosis and bone pain. The aim of our study was to highlight the role of sema3a on osteoblast differentiation of MC3T3-e1 in high-glucose condition and explore its therapeutic effect of diabetic osteopathy and . In our study, the expression of osteogenesis-related makers, such as ALP, OCN, OPG, β-catenin and Runx2, were analyzed in MC3T3 osteoblastic cells to explore the effect of sema3a on osteoblast differentiation in high-glucose condition, and as was the staining of ALP and Alizarin Red S. In a diabetic animal model, the expression of serum bone metabolic markers, such as ALP, P1NP, OCN, and β-CTX, were analyzed and micro-CT was used to detect bone architecture, including Tb.N, Tb.Th, Tb.Sp, Tb.Pf, BS/BV, and BV/TV after the treatment of sema3a. High glucose significantly inhibited osteogenic differentiation by decreasing the expression of osteogenesis-related makers, sema3a and its receptor of Nrp-1 in a dose-dependent manner in MC3T3. In high-glucose condition, exogenous sema3a (RPL917Mu01) increased the expression of ALP, OCN, OPG, Runx2, β-catenin, and the positive proportion of ALP and Alizarin Red S staining. In addition, in diabetic animal model, exogenous sema3a could increase bone mass and bone mineral density, and downregulate the expression of ALP, P1NP, OCN, and β-CTX. High glucose suppresses osteogenic differentiation in MC3T3 and sema3a may take part in this process. The application of exogenous sema3a alleviates high glucose-induced inhibition of osteoblast differentiation in diabetic osteopathy.

Citing Articles

Efficacy of lumbar and abdominal muscle rehabilitation training on degree of osteoporosis, pain and anxiety in elderly patients with osteoporotic vertebral compression fracture after PKP and compliance analysis.

Xu Y, Li D, Zhang Q, Tong L Front Med (Lausanne). 2024; 11:1364497.

PMID: 39005657 PMC: 11245735. DOI: 10.3389/fmed.2024.1364497.

FNDC5/irisin ameliorates bone loss of type 1 diabetes by suppressing endoplasmic reticulum stress‑mediated ferroptosis.

Dong Q, Han Z, Gao M, Tian L J Orthop Surg Res. 2024; 19(1):205.

PMID: 38555440 PMC: 10981808. DOI: 10.1186/s13018-024-04701-3.

Gastrodin improves osteoblast function and adhesion to titanium surface in a high glucose environment.

Li Y, Zhang J, Li F Biochem Biophys Rep. 2024; 37:101623.

PMID: 38225991 PMC: 10788200. DOI: 10.1016/j.bbrep.2023.101623.

Semaphorin 3A delivered by a rapidly polymerizing click hydrogel overcomes impaired implant osseointegration in a rat type 2 diabetes model.

Deng J, Cohen D, Sabalewski E, Van Duyn C, Wilson D, Schwartz Z Acta Biomater. 2022; 157:236-251.

PMID: 36435442 PMC: 10007856. DOI: 10.1016/j.actbio.2022.11.030.

Down-regulation of miR-340-5p promoted osteogenic differentiation through regulation of runt-related transcription factor-2 (RUNX2) in MC3T3-E1 cells.

Wang X, Mi Y, He W, Hu X, Yang S, Zhao L Bioengineered. 2021; 12(1):1126-1137.

PMID: 33818278 PMC: 8291863. DOI: 10.1080/21655979.2021.1905259.

References

Kruger R, Aurandt J, Guan K . Semaphorins command cells to move. Nat Rev Mol Cell Biol. 2005; 6(10):789-800. DOI: 10.1038/nrm1740. View

Janghorbani M, van Dam R, Willett W, Hu F . Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166(5):495-505. DOI: 10.1093/aje/kwm106. View

Potiron V, Nasarre P, Roche J, Healy C, Boumsell L . Semaphorin signaling in the immune system. Adv Exp Med Biol. 2007; 600:132-44. DOI: 10.1007/978-0-387-70956-7_11. View

Roth L, Koncina E, Satkauskas S, Cremel G, Aunis D, Bagnard D . The many faces of semaphorins: from development to pathology. Cell Mol Life Sci. 2008; 66(4):649-66. PMC: 11131483. DOI: 10.1007/s00018-008-8518-z. View

Pasterkamp R, Giger R . Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol. 2009; 19(3):263-74. PMC: 2730419. DOI: 10.1016/j.conb.2009.06.001. View

Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel R . Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011; 17(11):1473-80. DOI: 10.1038/nm.2489. View

Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H . Osteoprotection by semaphorin 3A. Nature. 2012; 485(7396):69-74. DOI: 10.1038/nature11000. View

Starup-Linde J . Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol (Lausanne). 2013; 4:21. PMC: 3591742. DOI: 10.3389/fendo.2013.00021. View

Fukuda T, Takeda S, Xu R, Ochi H, Sunamura S, Sato T . Sema3A regulates bone-mass accrual through sensory innervations. Nature. 2013; 497(7450):490-3. DOI: 10.1038/nature12115. View

10.

Dhaliwal R, Cibula D, Ghosh C, Weinstock R, Moses A . Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int. 2014; 25(7):1969-73. DOI: 10.1007/s00198-014-2704-7. View

11.

Bartell S, Kim H, Ambrogini E, Han L, Iyer S, Serra Ucer S . FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014; 5:3773. PMC: 4015330. DOI: 10.1038/ncomms4773. View

12.

Worzfeld T, Offermanns S . Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov. 2014; 13(8):603-21. DOI: 10.1038/nrd4337. View

13.

Huang Q, Jiang Z, Meng T, Yin H, Wang J, Wan W . MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. Biochem Biophys Res Commun. 2014; 453(1):160-5. DOI: 10.1016/j.bbrc.2014.09.076. View

14.

Starup-Linde J, Vestergaard P . Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2015; 82:69-78. DOI: 10.1016/j.bone.2015.02.019. View

15.

Song D, Meng T, Xu W, Hou T, Lin Z, Yin H . 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis. Bone. 2015; 78:46-54. DOI: 10.1016/j.bone.2015.04.047. View

16.

Picke A, Gordaliza Alaguero I, Campbell G, Gluer C, Salbach-Hirsch J, Rauner M . Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. Bone. 2015; 82:108-15. DOI: 10.1016/j.bone.2015.06.001. View

17.

Yu S, Zhang C, Xu X, Sun J, Zhang L, Yu P . Ursolic acid derivative ameliorates streptozotocin-induced diabestic bone deleterious effects in mice. Int J Clin Exp Pathol. 2015; 8(4):3681-90. PMC: 4466936. View

18.

Kwon S, Shin J, Kim I, Park D . Association of Plasma Semaphorin 3A With Phenotypes of Diabetic Retinopathy and Nephropathy. Invest Ophthalmol Vis Sci. 2016; 57(7):2983-9. DOI: 10.1167/iovs.16-19468. View

19.

Liu Y, Han X, Bo J, Ma H . Wedelolactone Enhances Osteoblastogenesis but Inhibits Osteoclastogenesis through Sema3A/NRP1/PlexinA1 Pathway. Front Pharmacol. 2016; 7:375. PMC: 5067540. DOI: 10.3389/fphar.2016.00375. View

20.

Ma R, Wang L, Zhao B, Liu C, Liu H, Zhu R . Diabetes Perturbs Bone Microarchitecture and Bone Strength through Regulation of Sema3A/IGF-1/β-Catenin in Rats. Cell Physiol Biochem. 2017; 41(1):55-66. DOI: 10.1159/000455936. View